Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 7.5% - Time to Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) traded up 7.5% during trading on Monday . The stock traded as high as $10.08 and last traded at $9.95. 973,595 shares traded hands during mid-day trading, an increase of 77% from the average session volume of 548,727 shares. The stock had previously closed at $9.25.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on BCAX shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a report on Friday, May 16th. Wall Street Zen lowered Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Wedbush reissued an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Friday, May 23rd. Finally, Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.86.

Bicara Therapeutics Trading Up 1.4%

The firm has a 50-day moving average price of $12.39 and a 200 day moving average price of $14.25.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). On average, sell-side analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Red Tree Management LLC purchased a new position in shares of Bicara Therapeutics in the 4th quarter worth approximately $55,230,000. Vestal Point Capital LP boosted its holdings in shares of Bicara Therapeutics by 290.0% during the 1st quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company's stock worth $36,080,000 after purchasing an additional 2,058,975 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Bicara Therapeutics by 171.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock worth $37,893,000 after buying an additional 1,375,265 shares during the last quarter. Braidwell LP lifted its holdings in shares of Bicara Therapeutics by 8.1% in the 1st quarter. Braidwell LP now owns 2,162,803 shares of the company's stock worth $28,181,000 after acquiring an additional 162,144 shares during the last quarter. Finally, Deep Track Capital LP boosted its stake in shares of Bicara Therapeutics by 151.0% in the fourth quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock valued at $34,840,000 after purchasing an additional 1,203,148 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.